Evidence map›Paper›PMID 41368474›Full record

ArticleCurrent hepatology reports2025

Met-ALD and ALD- Does Differentiating These Impact Management and Clinical Outcomes?

Fatima Elmustafa, Mahima Tyagi, Harpreet Kaur, Hanna Blaney, Chencheng Xie, Sajid Jalil, Ashwani K Singal

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Current hepatology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Fatima ElmustafaHealth and Jewish Hospital Transplant Hepatologist, University of Louisville School of Medicine, Physician University of Louisville Physicians Group, Hepatologist University of Louisville, Robley Rex VA Medical Center, Louisville, KY 40206, USA.
Mahima TyagiHealth and Jewish Hospital Transplant Hepatologist, University of Louisville School of Medicine, Physician University of Louisville Physicians Group, Hepatologist University of Louisville, Robley Rex VA Medical Center, Louisville, KY 40206, USA.
Harpreet KaurHealth and Jewish Hospital Transplant Hepatologist, University of Louisville School of Medicine, Physician University of Louisville Physicians Group, Hepatologist University of Louisville, Robley Rex VA Medical Center, Louisville, KY 40206, USA.
Hanna BlaneyHealth and Jewish Hospital Transplant Hepatologist, University of Louisville School of Medicine, Physician University of Louisville Physicians Group, Hepatologist University of Louisville, Robley Rex VA Medical Center, Louisville, KY 40206, USA.ORCID 0000-0003-4919-9519
Chencheng XieHealth and Jewish Hospital Transplant Hepatologist, University of Louisville School of Medicine, Physician University of Louisville Physicians Group, Hepatologist University of Louisville, Robley Rex VA Medical Center, Louisville, KY 40206, USA.
Sajid JalilHealth and Jewish Hospital Transplant Hepatologist, University of Louisville School of Medicine, Physician University of Louisville Physicians Group, Hepatologist University of Louisville, Robley Rex VA Medical Center, Louisville, KY 40206, USA.ORCID 0000-0003-2315-2384
Ashwani K SingalHealth and Jewish Hospital Transplant Hepatologist, University of Louisville School of Medicine, Physician University of Louisville Physicians Group, Hepatologist University of Louisville, Robley Rex VA Medical Center, Louisville, KY 40206, USA.

Funding

Integrated therapies for alcohol use and ALD (ITAALD) Network -UofL Clinical CenterU01AA026980 · NIAAA · UNIVERSITY OF LOUISVILLE · PI CRAIG J. MCCLAIN, Ashwani K Singal · 2018 to 2026
$2.9M
NIAAA NIH HHS U01 AA026980
6 · The paper itself

Abstract

Purpose of Review: The new nomenclature of steatotic liver disease overcame the stigma associated with non-alcohol fatty liver disease term changing to metabolic dysfunction associated steatototic liver disease (MASLD), and introduced a new entity of metabolic dysfunction and alcohol associated liver disease or Met-ALD. Introducing MetALD as a distinct clinical entity is challenging in clinical practice, but at the same time brings in opportunities for research to understand the various aspects of risk stratification, prognosis and natural history, pharmacological management, and designing clinical trials. This article delves into all these aspects of Met-ALD. Recent Findings: This overview provides new insights in the disease and pathogenesis of liver injury with interaction and pathways driven by both the risk factors of cardiometabolic risk factors and of alcohol use in patients with Met-ALD. Summary: MetALD is a distinct form of steatotic liver disease with phenotype overlapping both MASLD and alcohol associated liver disease (ALD). It addresses a key clinical reality that

Indexed as

Cardiometabolic risk factors (CMRF)Metabolic dysfunction and alcohol associated liver disease (Met-ALD)Metabolic dysfunction-associated steatotic liver disease (MASLD)Type 2 Diabetes Mellitus (T2DM)

Identifiers

PMID41368474
PMCPMC12685070

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.